ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity

  • Authors:
    • Donatas Stakišaitis
    • Milda Juknevičienė
    • Albertas Ulys
    • Dalia Žaliūnienė
    • Daiva Stanislovaitienė
    • Ramunė Šepetienė
    • Anželika Slavinska
    • Kęstutis Sužiedėlis
    • Vita Lesauskaitė
  • View Affiliations

  • Published online on: May 21, 2018     https://doi.org/10.3892/ol.2018.8749
  • Pages: 1321-1331
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to assess the ABO blood group polymorphism association with prostate, bladder and kidney cancer, and longevity. The following data groups were analyzed: Prostate cancer (n=2,200), bladder cancer (n=1,530), renal cell cancer (n=2,650), oldest‑old (n=166) and blood donors (n=994) groups. The data on the ABO blood type frequency and odds ratio in prostate cancer patients revealed a significantly higher blood group B frequency (P<0.05); the pooled men and women, separate men bladder cancer risk was significantly associated with the blood group B (P<0.04); however, no such association was identified in the female patients. The blood group O was observed to have a significantly decreased risk of bladder cancer for females (P<0.05). No significance for the ABO blood group type in the studied kidney cancer patients was identified. A comparison of the oldest‑old and blood donor groups revealed that blood group A was significantly more frequent and blood type B was significantly rarer in the oldest‑olds (P<0.05). The results of the present study indicated that blood type B was associated with the risk of prostate and bladder cancer, and could be evaluated as a determinant in the negative assocation with longevity. Blood types O and A may be positive factors for increasing the oldest‑old age likelihood. The clustering analysis by the ABO type frequency demonstrated that the oldest‑olds comprised a separate cluster of the studied groups.
View Figures
View References

Related Articles

Journal Cover

July 2018
Volume 16 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Stakišaitis, D., Juknevičienė, M., Ulys, A., Žaliūnienė, D., Stanislovaitienė, D., Šepetienė, R. ... Lesauskaitė, V. (2018). ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity. Oncology Letters, 16, 1321-1331. https://doi.org/10.3892/ol.2018.8749
MLA
Stakišaitis, D., Juknevičienė, M., Ulys, A., Žaliūnienė, D., Stanislovaitienė, D., Šepetienė, R., Slavinska, A., Sužiedėlis, K., Lesauskaitė, V."ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity". Oncology Letters 16.1 (2018): 1321-1331.
Chicago
Stakišaitis, D., Juknevičienė, M., Ulys, A., Žaliūnienė, D., Stanislovaitienė, D., Šepetienė, R., Slavinska, A., Sužiedėlis, K., Lesauskaitė, V."ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity". Oncology Letters 16, no. 1 (2018): 1321-1331. https://doi.org/10.3892/ol.2018.8749